Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · May 25, 2023

Keywords

ClinConnect Summary

The MAPEG 2 study is looking into how taste function changes in people with cognitive disorders, including those with early signs of Alzheimer's disease. Researchers want to compare taste experiences in four groups: healthy individuals, those with cognitive complaints but normal tests, those with minor cognitive impairment, and those with mild to moderate Alzheimer's. By conducting taste tests, measuring brain responses through sensors on the scalp, and checking nutritional factors through blood tests, the study aims to identify early taste changes that could help doctors diagnose Alzheimer's sooner and understand who might be at risk for developing the disease in the future.

To participate, individuals must be between the ages of 65 and 74, provide consent, and have a body mass index (BMI) under 30. Healthy participants should not have any cognitive complaints, while others must meet specific criteria related to their cognitive health. Participants can expect to undergo taste tests and other evaluations, and their findings may contribute to better diagnosis and management of Alzheimer's disease. This study is currently recruiting participants, and it’s essential for potential candidates to discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Person who has given oral consent.
• • For patients with mild to moderate Alzheimer\'s disease, the primary caregiver and the patient will be asked to provide oral consent
• • Person of legal age
• • Body Mass Index (BMI) \< 30 kg/m².
• • For the healthy group: absence of cognitive complaints and normal neurological assessment
• • Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation
• • Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5
• • Patients meeting diagnostic criteria for mild to moderate Alzheimer\'s disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5
• • Fasting for at least 2 hours before GEP measurement
• Exclusion Criteria:
• • MMSE score\<15
• • Known COVID-19 infection within 6 months prior to inclusion
• • Person not affiliated to national health insurance system
• • Person under a legal protection measure (curatorship, guardianship)
• • Person subject to a measure of legal protection
• • Pregnant, parturient or breastfeeding women
• • Subjects with a pacemaker (contraindication to bioelectrical impedance measurement)
• • Adult unable to express consent or to perform cognitive tests.
• • Active smoker (\> 4 cigarettes per day on a regular basis)
• • Diabetic subject (type 1 or type 2)
• • Subject with acute or chronic ENT disease
• • Treatment interfering with gustation
• • Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)